Comparative analysis of therapeutic options used for myasthenia gravis

Annals of Neurology

Volumn 68, Issue 6, 2010, Pages 797-805

  Mandawat, Aditya ^a   Kaminski, Henry J ^b   Cutter, Gary ^c   Katirji, Bashar ^a   Alshekhlee, Amer ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; AGE; AGED; ANAPHYLAXIS; ARTICLE; BACTEREMIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION COST; HUMAN; HYPERCOAGULABILITY; HYPERVOLEMIA; HYPOTENSION; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONEY; MORTALITY; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; SEPTICEMIA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMMUNITY HEALTH PLANNING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; ODDS RATIO; PLASMAPHERESIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650859575     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22139     Document Type: Article

References (30)

1. Naik AD, Petersen LA., The neglected purpose of comparative-effectiveness research. N Engl J Med 2009; 360: 1929-1931.
2. Johnston SC, Hauser SL., Comparative effectiveness research in the neurosciences. Ann Neurol 2009; 65: A6-A8.
3. Pinching AJ, Peters DK., Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2: 1373-1376.
4. El-Bawab H, Hajjar W, Rafay M, et al. Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols. Eur J Cardiothorac Surg 2009; 35: 392-397.
5. Trikha I, Singh S, Goyal V, et al. Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial. J Neurol 2007; 254: 989-995.
6. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106-175.
7. Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 840-843.
8. Linker RA, Gold R., Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 2008; 21: 358-365.
9. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-796.
10. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005; 62: 1689-1693.
11. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26: 549-552.
12. Zinman L, Ng E, Bril V., IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837-841.
13. Rønager J, Ravnborg M, Hermansen I, Vorstrup S., Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001; 25: 967-973.
14. Gajdos P, Chevret S., Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci 2008; 1132: 271-275.
15. Gajdos P, Chevret S, Toyka K., Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;(1):CD002277.
16. Dalakas MC., Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291: 2367-2375.
17. Charlson ME, Pompei P, Ales KA, MacKenzie CR., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
18. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
19. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009; 72: 1548-1554.
20. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52: 629-632.
21. Gold R, Stangel M, Dalakas MC., Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3: 36-44.
22. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009; 66: 1334-1338.
23. Hofstad H, Ohm O-J, Mørk SJ, Aarli JA., Heart disease in myasthenia gravis. Acta Neurol Scand 1984; 70: 176-184.
24. Rodnitzky RL, Goeken JA., Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39: 350-354.
25. Grgicevic D., Influence of long-term plasmapheresis on blood coagulation. Ric Clin Lab 1983; 13: 21-31.
26. Ovali E, Ratip S, Özmenoglu M, et al. Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis. Transfus Apher Sci 2003; 28: 201-206.
27. Juel VC., Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24: 75-81.
28. Madore F, Lazarus J, Brady H., Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7: 367-386.
29. Hardy MA, Bryman A., Handbook of data analysis. Thousand Oaks, CA: Sage Publications, 2004.
30. Cohen J., Applied multiple regression/correlation analysis for the behavioral sciences. 3rd ed., Mahwah, NJ,: L. Erlbaum Associates, 2003.